(Total Views: 106)
Posted On: 08/17/2022 2:09:11 PM
Post# of 44089
$RGC has performed quite well since April 2022, with share prices making a swing above $30. The recovery of the stock performance comes from positive clinical results related to the company's RGC-COV19 TCM formula.
From our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response.
From our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response.
(0)
(0)
